SLG
TOVX icon

Stanley-Laman Group’s Theriva Biologics TOVX Stock Holding History

Stanley-Laman Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7
Closed -$19K – 275
2018
Q1 		$19K Hold
7
– – ﹤0.01% 261
2017
Q4 		$31K Hold
7
– – 0.01% 267
2017
Q3 		$56K Buy
+7
New +$40.5K 0.01% 204

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stanley-Laman Group's TOVX Position: Q2 2018 in Review

Stanley-Laman Group sold out of Theriva Biologics (TOVX) in Q2 2018, closing a stake of 7 shares — an estimated $19K sold.

Stanley-Laman Group first reported a position in TOVX in Q3 2017 and held it in 3 quarters. The position peaked at $56K in Q3 2017. 46 funds tracked by Wall St. Rank hold TOVX as of Q2 2018.

  • Stanley-Laman Group reported no remaining Theriva Biologics position as of Q2 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 7 Theriva Biologics shares in Q2 2018, an estimated $19K.
  • Stanley-Laman Group first reported a position in Theriva Biologics in Q3 2017 and held it in 3 quarters.
  • Stanley-Laman Group's Theriva Biologics position peaked at $56K in Q3 2017.
  • 46 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2018.

Based on Stanley-Laman Group's 13F filing for Q2 2018, filed 9 Aug 2018.